WeightWatchers announced Friday that CEO Sima Sistani is no longer at the company, and independent board member Tara Comonte ...

GLP-1 medications—like Ozempic, Wegovy, and Zepbound—can help you shed pounds, but only if taken properly. Don't get caught ...

People with type 2 diabetes and obesity who develop kidney disease may benefit more from bariatric surgery than from GLP-1 ...

International said Friday that CEO Sima Sistani is stepping down immediately. She will be replaced by Tara Comonte, a board ...

According to health experts, if you eat the right foods, your body will trigger the natural release of GLP-1 – which is what ...

Results of the human clinical trial will be shared with LifeVantage Consultants at Market Connect in Kansas City, October ...

Sima Sistani, who took up the CEO post at WW International two-and-a-half years ago, is out, according to the company.

The diet and weight-loss brand, which has struggled to adapt in the Ozempic era, is losing its latest chief executive after ...

Ozempic continues to surge in popularity for managing type 2 diabetes and off-label weight loss, but are there natural ...

It’s similar with multiple sclerosis. Actually, there are so many good drugs out there. A lot of the market has already been ...

About 40% of U.S. adults suffer from obesity, and the cost of covering GLP-1 agonists and related anti-obesity drugs can be ...

The company's shares have plummeted about 90 percent this year due to the rising popularity of GLP-1 drugs like Ozempic and ...